• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Lorigan, Paul C
    Eggermont, A
    Affiliation
    Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK
    Issue Date
    2019
    
    Metadata
    Show full item record
    Citation
    Lorigan P, Eggermont AMM. Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop. Ann Oncol. 2019.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/621931
    DOI
    10.1093/annonc/mdz182
    PubMed ID
    31218362
    Additional Links
    https://dx.doi.org/10.1093/annonc/mdz182
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1093/annonc/mdz182
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    • Authors: Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR Jr, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS
    • Issue date: 2021 May
    • Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
    • Authors: Jacobsoone-Ulrich A, Jamme P, Alkeraye S, Dzwiniel V, Faure E, Templier C, Mortier L
    • Issue date: 2016 Apr
    • (18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma.
    • Authors: Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, Herschtal A, Fullerton S, Milne D, Iravani A, McArthur GA, Hicks RJ
    • Issue date: 2020 May 14
    • Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    • Authors: Almutairi AR, Erstad BL, McBride A, Slack M, Abraham I
    • Issue date: 2021 Apr
    • Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma.
    • Authors: Lai-Kwon J, Jacques S, Carlino M, Benannoune N, Robert C, Allayous C, Baroudjian B, Lebbe C, Zimmer L, Eroglu Z, Topcu TO, Dimitriou F, Haydon A, Lo SN, Menzies AM, Long GV
    • Issue date: 2023 Jun
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.